Pacific Biosciences of California, Inc.(PACB), a biotechnology-based sequencing solutions manufacturer, reported fourth-quarter and full-year 2025 results with a narrowed adjusted net loss as well as revenue growth.
For the fourth quarter, adjusted net loss shrank to $37.58 million from $55.34 million in the last year.
On a per-share basis, basic adjusted net loss shrank to $0.12 from $0.20 a year ago.
The firm reported a net loss of $40.37 million, compared with a net income of $2.37 million in the prior year.
On a per share basis, the loss narrowed to $0.13 per share from $0.49 in the year ago period.
Total revenue for the fourth quarter increased to $44.65 million from $39.22 million a year ago.
"Our fourth quarter results exceeded expectations, with revenue growing 14% year-over-year and 16% sequentially," said Christian Henry, President and CEO of PacBio.
For the full year, adjusted net loss narrowed to $157.78 million from $227.98 million in the prior year.
On a per-share basis, basic adjusted net loss shrank to $0.53 from $0.83 a year ago.
Net loss widened to $546.38 million from $309.85 million last year.
On a per share basis, net loss widened to $1.82 from $1.59 in the prior year.
For the full year 2025, total revenue increased to $160.01 million from $154.01 million a year ago.
Pacific Biosciences's products and technologies, include long-read sequencing, address solutions across research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
PACB closed Thursday's trade at $1.84.In the overnight market, the stock is up 0.54% at $1.85.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.